Q3 EPS Forecast for Repare Therapeutics Increased by Analyst

Repare Therapeutics Inc. (NASDAQ:RPTX) – HC Wainwright raised their Q3 2025 earnings per share estimates for shares of Repare Therapeutics in a note issued to investors on Monday, October 27th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.35) per share for the quarter, up from their previous estimate of ($0.49). HC Wainwright has a “Buy” rating and a $3.00 price target on the stock. The consensus estimate for Repare Therapeutics’ current full-year earnings is ($2.04) per share. HC Wainwright also issued estimates for Repare Therapeutics’ Q4 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.73) EPS.

RPTX has been the topic of several other research reports. Wall Street Zen raised Repare Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.50.

Repare Therapeutics Stock Performance

NASDAQ:RPTX opened at $1.78 on Wednesday. The stock’s fifty day moving average is $1.76 and its 200 day moving average is $1.54. Repare Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $4.07. The firm has a market capitalization of $76.47 million, a PE ratio of -0.69 and a beta of 1.08.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.39) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.17. The company had revenue of $0.25 million for the quarter, compared to analysts’ expectations of $2.50 million.

Hedge Funds Weigh In On Repare Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Quinn Opportunity Partners LLC bought a new position in shares of Repare Therapeutics during the 2nd quarter worth $56,000. XTX Topco Ltd purchased a new stake in shares of Repare Therapeutics during the 2nd quarter worth $60,000. Affinity Asset Advisors LLC lifted its stake in shares of Repare Therapeutics by 100.0% during the 1st quarter. Affinity Asset Advisors LLC now owns 200,000 shares of the company’s stock worth $197,000 after purchasing an additional 100,000 shares during the last quarter. Militia Capital Partners LP purchased a new stake in shares of Repare Therapeutics during the 2nd quarter worth $166,000. Finally, Acadian Asset Management LLC lifted its stake in shares of Repare Therapeutics by 35.6% during the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock worth $624,000 after purchasing an additional 168,230 shares during the last quarter. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.